Search research articles
Contact Us
Filters
Showing results (61-70 of 220) with videos related to
Page
of 22
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 23, 2014
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
Clinton F Stewart, Michael Tagen, Lee S Schwartzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2010
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma
Trevor McKibbin, John C Panetta, Maryam Fouladi, et al.
Journal of Pediatric Hematology/Oncology
|
November 16, 2004
Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma
Kristine R Crews, Clinton F Stewart, Tiebin Liu, et al.
Cancer Chemotherapy and Pharmacology
|
January 6, 2015
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing
Mina Nikanjam, Clinton F Stewart, Chris H Takimoto, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2007
In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
Judith A Smith, Anjali Gaikwad, Jiang Yu, et al.
Clinical Pharmacokinetics
|
August 22, 2015
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
Megan O Jacus, Vinay M Daryani, K Elaine Harstead, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 22, 2002
The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model
Helen M Dodds, Peter J Tobin, Clinton F Stewart, et al.
Biomedical Chromatography : BMC
|
March 12, 2009
Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood
K Elaine Hubbard, Paula Schaiquevich, Feng Bai, et al.
Cancer Research
|
April 3, 2004
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
Peter J Houghton, Glen S Germain, Franklin C Harwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420
Alberto Broniscer, John C Panetta, Melinda O'Shaughnessy, et al.
Page
of 22
Search research articles
Search
Showing results (61-70 of 220) with videos related to
Sort By:
Page
of 22
Cancer Chemotherapy and Pharmacology
|
January 23, 2014
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
Clinton F Stewart, Michael Tagen, Lee S Schwartzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2010
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma
Trevor McKibbin, John C Panetta, Maryam Fouladi, et al.
Journal of Pediatric Hematology/Oncology
|
November 16, 2004
Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma
Kristine R Crews, Clinton F Stewart, Tiebin Liu, et al.
Cancer Chemotherapy and Pharmacology
|
January 6, 2015
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing
Mina Nikanjam, Clinton F Stewart, Chris H Takimoto, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2007
In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
Judith A Smith, Anjali Gaikwad, Jiang Yu, et al.
Clinical Pharmacokinetics
|
August 22, 2015
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
Megan O Jacus, Vinay M Daryani, K Elaine Harstead, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 22, 2002
The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model
Helen M Dodds, Peter J Tobin, Clinton F Stewart, et al.
Biomedical Chromatography : BMC
|
March 12, 2009
Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood
K Elaine Hubbard, Paula Schaiquevich, Feng Bai, et al.
Cancer Research
|
April 3, 2004
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
Peter J Houghton, Glen S Germain, Franklin C Harwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420
Alberto Broniscer, John C Panetta, Melinda O'Shaughnessy, et al.
Page
of 22